Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis
Yong W. Cho, Dong H. Yang, Do Y. Oh, Seung H. Baick, Sun K. Kim, Sun J. Kim, Sae Y. Hong
Korean J Intern Med. 1992;7(2):81-87. Published online 1992 Jul 1 DOI: https://doi.org/10.3904/kjim.1992.7.2.81
Citations to this article as recorded by 
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis
Nicolas Wiernsperger, Abdallah Al-Salameh, Bertrand Cariou, Jean-Daniel Lalau
Diabetes & Metabolism.2022; 48(4): 101359. CrossRef
Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model
Anna Gromotowicz-Poplawska, Piotr Szoka, Agnieszka Zakrzeska, Patrycjusz Kolodziejczyk, Natalia Marcinczyk, Janusz Szemraj, Piotr Tutka, Ewa Chabielska
Cells.2021; 10(2): 471. CrossRef
An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis
Magdalena Markowicz-Piasecka, Adrianna Sadkowska, Kristiina M. Huttunen, Maria Podsiedlik, Elżbieta Mikiciuk-Olasik, Joanna Sikora
European Journal of Pharmacology.2020; 872: 172984. CrossRef
Sulfenamide and sulfonamide derivatives of metformin can exert anticoagulant and profibrinolytic properties
Magdalena Markowicz-Piasecka, Kristiina M. Huttunen, Łukasz Mateusiak, Elżbieta Mikiciuk-Olasik, Joanna Sikora
Chemico-Biological Interactions.2018; 284: 126. CrossRef
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies
James Yarmolinsky, Natália Bordin Barbieri, Tobias Weinmann, Patricia K. Ziegelmann, Bruce B. Duncan, Maria Inês Schmidt
Scientific Reports.2016;[Epub] CrossRef
Short-Term Treatment with Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects with Type 2 Diabetes Mellitus who have a Metabolic Syndrome and Normal Glucose Tolerance without Changes in C-Reactive Protein or Fibrinogen
Luis Mauro Alvim de Lima, Nicolas Wiernsperger, Luiz Guilherme Kraemer-Aguiar, Eliete Bouskela
Clinics.2009; 64(5): 415. CrossRef
Beneficial effects of metformin on haemostasis and vascular function in man
P.J. Grant
Diabetes & Metabolism.2003; 29(4): 6S44. CrossRef
The Effect of Dimethylbiguanide on Thrombin Activity, FXIII Activation, Fibrin Polymerization, and Fibrin Clot Formation
Kristina F. Standeven, Robert A.S. Ariëns, Paul Whitaker, Alison E. Ashcroft, John W. Weisel, Peter J. Grant
Diabetes.2002; 51(1): 189. CrossRef
Metformin: Intrinsic Vasculoprotective Properties
Nicolas F. Wiernsperger
Diabetes Technology & Therapeutics.2000; 2(2): 259. CrossRef
Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus
R. Testa, A.R. Bonfigli, L. Piantanelli, S. Manfrini, I. Testa, F. Gregorio
Diabetes Research and Clinical Practice.1996; 33(2): 111. CrossRef
CARDIOVASCULAR EFFECTS OF ORAL HYPOGLYCAEMIC DRUGS
Laurence Guy Howes, Purnima Sundaresan, Denise Lykos
Clinical and Experimental Pharmacology and Physiology.1996; 23(3): 201. CrossRef
Altered lysis resistance of platelet-rich clots in patients with insulin-dependent diabetes mellitus
Miklos Udvardy, Emoke Posan, Jolan Harsfalvi
Thrombosis Research.1995; 79(1): 57. CrossRef
The effects of metformin on cardiovascular risk factors
Peter J. Grant
Diabetes/Metabolism Reviews.1995; 11(S1): S43. CrossRef